Cholesterol; Metabolic Disorder, CVD, Inflammation
Conditions
Keywords
enriched beef, omega, poly unsaturated fatty acids (PUFA), cholesterol, grass fed
Brief summary
Red meat is an integral component of the habitual diet among the UK and Irish population, with adults consuming an average of 71grams/day. Although typically high in saturated fatty acids (SFA), red meat is also an important dietary source of protein and essential nutrients including iron, zinc, B vitamins and long chain n-3 polyunsaturated fatty acids (PUFA) which provide numerous benefits to human health, particularly related to cardiovascular disease (CVD) risk. N-3 and n-6 PUFA are a family of fatty acids with important roles in cardiovascular health, and it is often recommended in dietary guidelines to replace SFA with unsaturated fats, such as PUFA. Owing to the social and economic burden of CVD, increasing the proportions of these unsaturated fatty acids, in combination with a reduction in SFA within meat, could have a large impact on CVD risk at the population level, whilst retaining the beneficial nutrients and n-3 PUFA which meat provides. In this research, a total of 90 eligible and consenting participants will be randomly allocated to consume three portions per week of n-3 enriched beef (from either dietary supplemented or grass-fed cattle) or control beef (from standard supply). This beef will be offered within a lunchtime meal and served from the Human Intervention Studies Unit at Ulster University, Coleraine for a period of 5 weeks. A fasting blood sample will be taken before and after intervention to determine the effect the n-3 enriched beef on cholesterol concentrations, lipid profile, PUFA status and inflammation. Blood pressure, stiffness of the arteries and body shape, size and composition will also be assessed, and some health and lifestyle habits will be captured using questionnaires.
Interventions
DIETARY_SUPPLEMENTThree portions per week (690g beef (raw weight)) for 5 weeks
Lunches served in Human Intervention Studies Unit
Sponsors
Dunbia, Northern Ireland
University of Ulster
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Masking description
Double blind
Intervention model description
Double blind randomised controlled trial
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Free-living, apparently healthy adults * Aged 20+ years at recruitment * Low oily fish consumers (\<2 servings/mo), or those willing to reduce their fish consumption 1 month prior to commencing the study * Non-smokers * Not regularly consuming plant stanols or other n-3 enriched foodstuffs
Exclusion criteria
* Non-free-living adults * Adults \<20 years at recruitment * Oily fish consumers (2 servings/mo or more) * Current smokers * Pregnant/lactating females (or planning to become pregnant) * Food allergy or intolerance that would prevent consumption of the study meals * Diagnosed with a chronic medical condition (such as diabetes; CVD; autoimmune/ inflammatory disorders; cancer) * Prescribed cholesterol or blood pressure lowering medications * Currently taking any fish oil-containing supplement Daily consumption of plant stanols or other n-3 enriched foodstuffs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cholesterol levels | Change at 5 weeks from baseline | Plasma cholesterol measured colormetrically |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Polyunsaturated fatty acid profile | Change at 5 weeks from baseline | Serum fatty acids measured by GC-MS |
| Pulse Wave Velocity | Change at 5 weeks from baseline | Measured by Sphygmocor XCEL |
| Lipid profile | Change at 5 weeks from baseline | Plasma lipids measured colormetrically |
| Whole body composition | Change at 5 weeks from baseline | Measured by Dual Energy X-ray Absorptiometry |
| Inflammation status | Change at 5 weeks from baseline | Measured by ELISA |
| Blood pressure | Change at 5 weeks from baseline | Measured by electronic blood pressure monitor |
Countries
United Kingdom
Outcome results
None listed